MedTrace Logo

Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer

NCT05002465 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2023-09-11

No results posted yet for this study

Summary

The purpose of this protocol is to provide 68Ga Prostate Specific Membrane Antigen-11 (68Ga PSMA-11) for clinical use in the diagnosis, staging and restaging of prostate cancer using Positron Emission Tomography with Computed Tomography (PET/CT) prior to its full local Federal Drug Administration (FDA) approval. Extensive research has shown that 68Ga PSMA-11 PET/CT offers higher detection rate of metastatic disease in prostate cancer than the current standard of care usually used in staging and restaging prostate cancer.

Conditions

Interventions

DRUG

68Ga-PSMA-11

Injection of 68Ga PSMA-11

PROCEDURE

Positron Emission Tomography/Computed Tomography

PET/CT scan after 68Ga PSMA-11 injection

Sponsors & Collaborators

  • Dana Mathews

    lead OTHER

Principal Investigators

  • Orhan K Oz, MD, PhD · UT Southwestern Medical Center

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05002465 on ClinicalTrials.gov